Dr. Reddy's Laboratories · NSE: DRREDDY · BSE: 500124

Q1 FY21 results · Apr–Jun 2020

Dr. Reddy's Laboratories reported revenue from operations of ₹4,426.50 crore (up 14.7% from Q1 FY20) and net profit of ₹594.60 crore (down 12.1% from Q1 FY20) for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY21	Q1 FY20	YoY	Q4 FY20	QoQ
Revenue from operations	4,426.50	3,858.20	+14.7%	4,448.90	−0.5%
Other income	87.10	430.10	−79.7%	73.60	+18.3%
Total income	4,513.60	4,288.30	+5.3%	4,522.50	−0.2%
Profit before share of associates & JVs and tax	892.80	853.00	+4.7%	725.70	+23.0%
Share of profit/(loss) of associates & JVs	7.70	16.30		10.50
Net profit for the period	594.60	676.50	−12.1%	781.10	−23.9%
Attributable to shareholders of the company	586.90	—	—	781.10	−24.9%
EPS, basic (₹)	35.87	40.81	−12.1%	47.12	−23.9%
Net margin (%)	13.4	17.5		17.6

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY21	Q1 FY20	YoY	Q4 FY20	QoQ
Revenue from operations	3,244.40	2,508.70	+29.3%	2,851.70	+13.8%
Other income	644.70	471.40	+36.8%	127.40	+406.0%
Total income	3,889.10	2,980.10	+30.5%	2,979.10	+30.5%
Profit before tax	1,361.70	693.00	+96.5%	444.10	+206.6%
Net profit for the period	950.20	548.10	+73.4%	502.80	+89.0%
EPS, basic (₹)	57.31	33.06	+73.3%	30.34	+88.9%
Net margin (%)	29.3	21.8		17.6

Consolidated

Filed with BSE: 29 Jul 2020, 14:53 IST
Board meeting: 29 Jul 2020
Period: 01 Apr 2020 to 30 Jun 2020
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 29 Jul 2020, 14:53 IST
Board meeting: 29 Jul 2020
Period: 01 Apr 2020 to 30 Jun 2020
Review status: Unaudited
Source: XBRL filing on BSE